Bactiguard launches product that protects against Coronavirus
Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15–30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this.
“As a result of the rapid spread of COVID-19 in both Europe and the Middle East, we see a strong interest in HYDROCYN aqua, a water-based product that kills bacteria, fungi and virus in seconds without damaging or irritating the body. Many companies that want to work preventively to protect their employees have already contacted us and started placing orders,” says Cecilia Edström, CEO.
“Our mission is to prevent infections and save lives. Therefore, we want to roll out the product across all markets in our distribution network as quickly as possible, following the acquisition of Vigilenz. At the same time, we are working hard to increase production capacity to meet the growing demand from both hospitals and companies, especially since there is a shortage of disinfectants in many markets,” continues Cecilia Edström.
The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15–30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska Institute to verify this.
HYDROCYN aqua® is a pH-neutral and water-based product that, unlike alcohol and chlorhexidine, isn’t toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). HYDROCYN aqua® is included in Bactiguard’s portfolio of products following the acquisition of Vigilenz. Read more at www.hydrocynaqua.com.
HYDROCYN aqua® is CE marked (EU approved) and FDA approved in the US.
For further information, please contact:
Cecilia Edström, CEO, phone +46 440 58 80
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com